Amendment to the claims

Claims 1, 2, 5-11, and 19-29 are currently pending. Claims 1, 5, 8, 20, 21, 22, 23, 24, 25, 26, 27, 28, and 29 are currently amended. Claim 2 has been deleted.

1. (Currently amended) A pharmaceutical composition comprising a solid dispersion of an HIV protease inhibitor or a combination of HIV protease inhibitors in a water soluble carrier wherein said water soluble carrier is polyethylene glycol 8000 (PEG 8000) and wherein the HIV protease inhibitor or the combination of HIV protease inhibitors is in amorphous form in the dispersion.

2. (Deleted) The composition of Claim 1 wherein said water soluble carrier is polyethylene glycol (PEG).

3.- 4. (Withdrawn)

5. (Currently amended) The composition of Claim 2 wherein said HIV protease inhibitor is selected from the group consisting of:
(2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir);
(2S, 3S, 5S)-2-(2,6Dimethylphenoxyacetyl) amino-3-hydroxy-5-[2S-(Ή1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl] amino-1,6-diphenylhexane (ABT-378); N-(2(R)-hydroxy-1 (S)-indanyl)-2(R)-phenylmethyl -4(S)-hydroxy-5-(Ή1-(4-(3-pyridylmethyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide (indinavir);

N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarb onyl)-L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide (saquinavir); 5(S)-Boc-amino-4(S)-hydroxy-6-phenyl-2(R)-phenylmethylhexanoyl-(L)-Val-(L)-Phe-morpholin-4-ylamide;
1 -Naphthoxyacetyl-beta-methylthio-Ala-(2S, 3S)-3-amino-2-hydroxy-4-butanoyl 1,3-thiazolidine-4- t-butylamide;
5-isoquinolinoxyacetyl-beta-methylthio-Ala-(2S,3S)-3-amino-2-hydroxy-4-b utanoyl-1,3-thiazolidine-4-t-butylamide; [1S-[1R-(R-),2S*]-N^{1}-[3-[[[(1,1 -dimethylethyl)amino]carbonyl](2-methylpropyl)amino]-2-hydroxy-1 -(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-butanediamide;
VX-478; DMP-323; DMP-450; AG1343 (nelfinavir);
BMS 186,318; SC-55389a; BILA 1096 BS; U-140690, and combinations thereof.

6. (Previously amended) The composition of Claim 2 wherein said HIV protease inhibitor is (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)1,6-diphenyl-3-hydroxyhexane (ritonavir).

7. (Original) The composition of Claim 2 wherein said HIV protease inhibitor is (2S,3S,5S)-2-(2,6-Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(l-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl] amino-1,6-diphenylhexane (ABT-378).

8. (Currently Amended) The composition of Claim 2 wherein said HIV protease inhibitor is a combination of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-

isopropyl-4-thiazolyl)methyl)amino)carbonyl)L-valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)- ~~amino-~~ 1,6-diphenyl-3-hydroxyhexane (ritonavir) and (2S,3S,5S)-2-(2,6-Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1~~H~~-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl] amino-1,6-diphenylhexane (ABT-378).

9. (Original) The composition of Claim 2 wherein said solid dispersion is encapsulated in a hard gelatin capsule.

10. (Original) The composition of Claim 2 wherein said solid dispersion is compressed into a tablet.

11. (Original) The composition of Claim 1 further comprising an additive or a mixture of additives independently selected from the group consisting of pharmaceutically acceptable surfactants and antioxidants.

12.-18. (Deleted)

19. (Original) A method of treating an HIV infection comprising administering an effective amount of a solid dispersion of Claim 1 to a mammal in need of such treatment.

20. (Currently Amended) The method of Claim 19 wherein said HIV protease inhibitor is selected from the group consisting of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-amino-1,6-

diphenyl-3-hydroxyhexane (ritonavir) and (2S,3S,5S)-2-(2,6-Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1H-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl] amino-1,6-diphenylhexane (ABT-378).

21. (Currently amended) The method of Claim 19 wherein said HIV protease inhibitor is a combination of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)L-valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) and (2S,3S,5S)-2-(2,6-Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1H-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl] amino-1,6-diphenylhexane (ABT-378).

22. (Currently Amended) A pharmaceutical composition comprising a solid dispersion of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)L-valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) in a water soluble carrier wherein the ritonavir is in amorphous form in the solid dispersion.

23. (Currently Amended) The composition of Claim 22 wherein said water soluble carrier is polyethylene glycol 8000 (PEG 8000).

24. (Currently Amended) A pharmaceutical composition comprising a solid dispersion of (2S,3S,5S)-2-(2,6-Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1H-tetrahydro-

pyrimid-2-onyl)-3-methyl butanoyl] amino-1,6-diphenylhexane (ABT-378) in a water soluble carrier wherein the ritonavir is in amorphous form in the solid dispersion.

25. (Currently Amended) The composition of Claim 24 wherein said water soluble carrier is polyethylene glycol 8000 (PEG 8000).

26. (Currently Amended) A pharmaceutical composition comprising a solid dispersion of a combination of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)L-valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) and (2S,3S,5S)-2-(2,6-Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1~~H~~-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl] amino-1,6-diphenylhexane (ABT-378)) in a water soluble carrier wherein the ritonavir is in amorphous form in the solid dispersion.

27. (Currently Amended) The composition of Claim 26 wherein said water soluble carrier is polyethylene glycol 8000 (PEG 8000).

28. (Currently Amended) A pharmaceutical composition comprising a solid dispersion of nelfinavir in a water soluble carrier wherein the nelfinavir is in amorphous form in the solid dispersion.

29. (Currently Amended) The composition of Claim 28 wherein said water soluble carrier is polyethylene glycol 8000 (PEG 8000).